Cargando…

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias

The KMT2A (MLL) gene rearrangements (KMT2A-r) are associated with a diverse spectrum of acute leukemias. Although most KMT2A-r are restricted to nine partner genes, we have recently revealed that KMT2A-USP2 fusions are often missed during FISH screening of these genetic alterations. Therefore, compl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopes, Bruno A., Poubel, Caroline Pires, Teixeira, Cristiane Esteves, Caye-Eude, Aurélie, Cavé, Hélène, Meyer, Claus, Marschalek, Rolf, Boroni, Mariana, Emerenciano, Mariana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208280/ https://www.ncbi.nlm.nih.gov/pubmed/35734412 http://dx.doi.org/10.3389/fphar.2022.749472

Ejemplares similares

KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
por: Bataller, Alex, et al.
Publicado: (2021)

The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome
por: Külp, Marius, et al.
Publicado: (2023)

Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
por: Brethon, Benoît, et al.
Publicado: (2021)

Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions
por: Meyer, Claus, et al.
Publicado: (2019)

ARID5B polymorphism confers an increased risk to acquire specific MLL rearrangements in early childhood leukemia
por: Emerenciano, Mariana, et al.
Publicado: (2014)

P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL
por: Kim, Rathana, et al.
Publicado: (2023)

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia
por: Külp, Marius, et al.
Publicado: (2022)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

The KMT2A recombinome of acute leukemias in 2023
por: Meyer, C., et al.
Publicado: (2023)

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
por: Stutterheim, Janine, et al.
Publicado: (2021)

Diagnostic Usefulness of Genomic Breakpoint Analysis of Various Gene Rearrangements in Acute Leukemias: A Perspective of Long Distance- or Long Distance Inverse-PCR-based Approaches
por: Yang, John Jeongseok, et al.
Publicado: (2012)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
por: Górecki, Mateusz, et al.
Publicado: (2023)

COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia
por: Lopes, Bruno Almeida, et al.
Publicado: (2016)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Cheung, Laurence C., et al.
Publicado: (2021)

The Partial Duplication of the 5′ Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia
por: Fukushima, Hiroko, et al.
Publicado: (2017)

IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia
por: Lopes, Bruno A., et al.
Publicado: (2019)

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
por: Hoffmeister, Lina Marie, et al.
Publicado: (2021)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

PAX5 alterations in an infant case of KMT2A‐rearranged leukemia with lineage switch
por: Nakajima, Koji, et al.
Publicado: (2022)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
por: Gaidzik, Verena I., et al.
Publicado: (2023)

Monocytic and blastic plasmacytoid dendritic cell differentiation in acute leukemia with KMT2A rearrangement
por: Xue, Owen, et al.
Publicado: (2023)

Discovery of fusion circular RNAs in leukemia with KMT2A::AFF1 rearrangements by the new software CircFusion
por: Dal Molin, Anna, et al.
Publicado: (2022)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions
por: Massoth, Lucas R., et al.
Publicado: (2020)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
por: Kang, Huining, et al.
Publicado: (2018)

A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report
por: Barbosa, Thayana Conceição, et al.
Publicado: (2018)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
por: Tregnago, Claudia, et al.
Publicado: (2022)

A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia
por: Harada, Taku, et al.
Publicado: (2022)

Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens
por: Wright, Shaela, et al.
Publicado: (2023)

P435: NOVEL COMPOUNDS TO TARGET KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Tregnago, Claudia, et al.
Publicado: (2023)

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia
por: Karsa, Mawar, et al.
Publicado: (2022)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2A-rearranged Leukemia
por: Esposito, Maria Teresa
Publicado: (2019)

FISH improves risk stratification in acute leukemia by identifying KMT2A abnormal copy number and rearrangements
por: Li, Qinlu, et al.
Publicado: (2022)

An alternative approach to confirm mixed lineage involvement in acute leukemia with KMT2A rearrangement– an illustrative report
por: Ray, Debadrita, et al.
Publicado: (2023)

Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement
por: Li, Jun, et al.
Publicado: (2023)

XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements
por: Louzada-Neto, Orlando, et al.
Publicado: (2020)

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
por: Burmeister, Thomas, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qb51v5kuiu75sa85j0od9dff6c